KVK Tech Revenue and Competitors

Newtown, PA USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • KVK Tech's estimated annual revenue is currently $49M per year.(i)
  • KVK Tech's estimated revenue per employee is $201,000

Employee Data

  • KVK Tech has 244 Employees.(i)
  • KVK Tech grew their employee count by 1% last year.

KVK Tech's People

NameTitleEmail/Phone
1
Head Facilities & EngineeringReveal Email/Phone
2
VP Sales MarketingReveal Email/Phone
3
VP, Business Development & Brand MarketingReveal Email/Phone
4
Head Information Systems & complianceReveal Email/Phone
5
Director OperationsReveal Email/Phone
6
Executive Director, Global QualityReveal Email/Phone
7
Associate Director Quality Management Systems (QMS)Reveal Email/Phone
8
ManagerReveal Email/Phone
9
QC ManagerReveal Email/Phone
10
Production managerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$43.2M2156%N/AN/A
#2
$81.8M40710%N/AN/A
#3
$11.7M580%N/AN/A
#4
$1011.8M5034-9%N/AN/A
#5
$44.8M2231%N/AN/A
#6
$13.1M655%N/AN/A
#7
$16.5M8241%N/AN/A
#8
$17.3M86-5%N/AN/A
#9
$67.9M33823%N/AN/A
#10
$14.9M747%N/AN/A
Add Company

What Is KVK Tech?

KVK is a leader in the development and manufacture of high-quality, FDA-approved medicines that address unmet patient needs. We take pride in our ability to advance medical care and offer low-cost alternatives in response to todayâ??s healthcare challenges. All of our products are manufactured, packaged and distributed by KVK in the United States.\r\n\r\nVISION: \r\n\r\nâ??By 2020, KVK will apply its relentless drive to manufacture high-quality, affordable generics in every major dosage form,â?? states Anthony Tabasso, CEO and President of KVK Tech. â??And, all of our products will be made in the USA, right here in Pennsylvania.â??\r\n\r\nKVK is committed to expansion through alliances across all phases of operations, which is evidenced by the current construction of a 250,000-square-foot sterile injectable plant in nearby Langhorne and the purchase of the 461,000-square-foot Lockheed-Martin complex in Newtown.\r\n\r\nWe continue to explore strategic opportunities to add to our expanding portfolio and are aggressively pursuing research and development prospects, including investment in new molecular entities.\r\n\r\nAnd, we continue with developments in oral solids, such as extended or slow release tablets or capsules, all the while maintaining high manufacturing standards and exemplary customer service.\r\n\r\n\r\nMISSION: \r\n\r\nTo continually build on our promise to deliver safe, effective and affordable FDA-approved pharmaceuticals to meet our customersâ?? needs and ensure that patients have access to high-quality medicines when they need it.\r\n\r\nOur confidence in our ability to execute and play a key role in the pharmaceutical marketplace is underscored by the dedication of our employees and their commitment to excellence in science, manufacturing, quality control, regulatory compliance and customer satisfaction.

keywords:N/A

N/A

Total Funding

244

Number of Employees

$49M

Revenue (est)

1%

Employee Growth %

N/A

Valuation

N/A

Accelerator

KVK Tech News

2022-04-06 - Hyperkalemia Drugs Market- 38% of Growth to Originate from ...

AdvaCare International, Ardelyx Inc., AstraZeneca Plc, CytoSorbents Corp., KVK Tech Inc., Sanofi SA, Steadfast MediShield Pvt. Ltd., and Vifor...

2022-03-22 - Sen-Jam and KVK Tech collaborate to develop Covid-19 oral ...

KVK Tech will offer formulation and chemistry, manufacturing and controls (CMC) for the oral therapy. Sen-Jam Pharmaceutical CEO Jim Iversen...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$60.5M2626%N/A
#2
$83.5M2814%N/A
#3
$56.8M287N/AN/A
#4
$66.9M306-1%N/A
#5
$67.4M5297%N/A